12:00 AM
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anti-NKG2a: Phase I started

Novo Nordisk disclosed in its 1H11 earnings that in May it began a double-blind, placebo-controlled, dose-escalation, German Phase I trial to evaluate single doses of subcutaneous and IV anti-NKG2a and multiple doses of subcutaneous anti-NKG2a in about...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >